Cell Therapy
Galapagos Halts CAR-T Cell Therapy Trial Due to Parkinsonism Case
Galapagos, CAR-T cell therapy, Parkinsonism, clinical trial, patient enrollment, BCMA-directed therapy, multiple myeloma
FDA Approves Johnson & Johnson’s New Multiple Myeloma Therapy
FDA approval, Johnson & Johnson, multiple myeloma, CAR-T cell therapy, bispecific antibody, TALVEY, CARVYKTI, DARALEXASPRO
Caribou Biosciences Discontinues CAR-NK Program, Lays Off 21 Employees to Focus on CAR-T Cell Therapies
Caribou Biosciences, CAR-NK, CAR-T, cell therapy, layoffs, biotech, cancer treatment, autoimmune diseases
Artiva Biotherapeutics Seeks $116M in Second IPO Attempt for Cell Therapy Development
Artiva Biotherapeutics, IPO, cell therapy, AlloNK, systemic lupus erythematosus, autoimmune diseases
Biotech Faces a Reckoning: The Challenges and Shifts in Cell Therapies
cell therapy, biotech, gene therapy, autoimmune diseases, manufacturing challenges, market acceptance, pharmaceutical industry
Revolutionizing Healthcare: Streamlining Cell and Gene Therapy Manufacturing (Part 1)
Cell therapy, gene therapy, manufacturing, biotechnology, healthcare innovation, personalized medicine, production challenges, regulatory compliance, scalability, cost-effectiveness.
Revolutionizing Medicine: The Evolution and Future of Cell and Gene Therapy Manufacturing
Cell therapy manufacturing, gene therapy manufacturing, biomanufacturing, advanced therapies, CAR-T cell therapy, stem cell therapy, viral vectors, bioreactors, automation, scale-up, regulatory compliance, personalized medicine.
AstraZeneca Strengthens Partnership with Cellectis in Cell and Gene Therapy Advancement
AstraZeneca, Cellectis, cell therapy, gene therapy, partnership, stake, discovery, pact, biotechnology, healthcare, investment, innovation, medical research, therapeutic development.
BMS-Cellares Collaboration Spotlights U.S.-China Biopharma Rivalry
BMS, Cellares, CAR-T, collaboration, U.S.-China tensions, biopharma rivalry, cell therapy, cancer treatment.
FDA Issues Complete Response Letter to Abeona’s Cell Therapy for Rare Skin Disease
FDA, Complete Response Letter (CRL), Abeona, cell therapy, rare skin disease, Epidermolysis Bullosa (EB)